This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.
Katja Weisel, MD
Advertisement
Articles by Katja Weisel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
4
Neoadjuvant Strategies and Early Biomarker Testing in EGFR-Mutated NSCLC
5